Diabetes Therapy

Actos shows sustained efficacy over 2-year period

Published in Obesity and Diabetes Week, July 5th, 2004

Long-term studies using the oral antidiabetic drug Actos (pioglitazone HCl) alone, and in combination with other oral antidiabetic medications, found that it provided sustained improvements in glycemic control, insulin sensitivity and key lipid parameters over a 104-week period.

The findings were presented at the American Diabetes Association's (ADA) 64th Annual Scientific Sessions.

"Given the clinical challenges of managing diabetes patients over time, and the fact that patients are living longer with diabetes, the data being presented on Actos help physicians better understand the drug's effectiveness over an extended period," said Mehmood Khan,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-07-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry